Highlights Abbisko Cayman Limited

Equities

2256

KYG0028A1085

Market Closed - Hong Kong S.E. Other stock markets 09:08:35 13/05/2024 BST			5-day change	1st Jan Change
3.47 ^HKD	+0.58%		-3.07%	-4.93%

05-09	Abbisko Cayman Unit's Cancer Drug To Be Clinically Tested in Combination with Shanghai Allist's Furmonertinib	MT
04-29	Abbisko Cayman Limited Appoints Yu Hongping as Joint Company Secretaries	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Abbisko Cayman Limited Voluntary Announcement FGFR4 Inhibitor Irpagratinib Granted Odd by FDA	04-25	CI
Abbisko Cayman's Unit Presents Pre-Clinical Study of Liver Cancer Drug at AACR Annual Meeting	04-10	MT
Abbisko Cayman Completes Patient Enrollment for Phase 3 Trial of Joint Tumor Treatment	04-09	MT
Abbisko Therapeutics Co., Ltd. Completes All Patient Enrollment for the Global Phase III TGCT Trial of Its CSF-1R Inhibitor - Pimicotinib	04-09	CI
Abbisko Cayman's Attributable Loss Narrows as Revenue, Other Gains Rise	03-14	MT
Abbisko Cayman to Buy Back, Cancel Up to HK$100 Million Shares	03-13	MT
Abbisko Cayman Limited commences an Equity Buyback for 70,219,935 shares, representing 10% of its issued share capital, under the authorization approved on June 14, 2023.	03-12	CI
Abbisko Cayman Limited Reports Earnings Results for the Full Year Ended December 31, 2023	03-12	CI
Abbisko Therapeutics Co., Ltd. Completes the First Patient Dose in the Clinical Trial for Its Next-Generation CD73 Inhibitor ABSK051	01-02	CI
Abbisko Cayman Unit Gets US FDA Fast-Track Status for Tenosynovial Giant Cell Tumor Treatment	12-14	MT
Abbisko Therapeutics Announces U.S. FDA Grants Fast Track Designation for CSF-1R Inhibitor Pimicotinib	12-14	CI
Abbisko Therapeutics Completed the First Patient Dose in the Phase II Advanced Pancreatic Cancer Trial of CSF-1R Inhibitor Pimicotinib in China	11-27	CI
Abbisko Therapeutics Co., Ltd. Obtains the Clinical Trial Approval from NMPA for its Next-Generation Small Molecule CD73 Inhibitor ABSK051	11-08	CI
Abbisko Therapeutics Co., Ltd. Presents Two Clinical Updates of Pimicotinib at the 2023 Connective Tissue Oncology Society Annual Meeting	11-07	CI
Abbisko Cayman Unit to Present Data on Tenosynovial Giant Cell Tumor Drug at Conference; Shares Rise 10%	30/10/23	MT
Abbisko Cayman Limited to Debut Two Major Clinical Research Results At the 2023 European Society for Medical Oncology	16/10/23	CI
China Gives Green Light to Abbisko Cayman Arm's Phase 2 Trial for Liver Cancer Treatment	26/09/23	MT
Abbisko Cayman Limited Announces Absk011 Hcc Combo Clinical Trial Approved by Nmpa	25/09/23	CI
Abbisko Cayman's H1 Loss Widens	16/08/23	MT
Abbisko Cayman Limited Reports Earnings Results for the Half Year Ended June 30, 2023	15/08/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Abbisko Cayman Limited

Equities

2256

KYG0028A1085

Highlights

Filters